AzTrials
AzTrials

Drug-induced Extrapyramidal Side EffectsNCT02366897

Extrapyramidal Side-Effects in Antipsychotic Drug Therapeutics

A study testing Manus Sensor Pen in people with Drug-induced Extrapyramidal Side Effects, run by University of Edinburgh at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The project is aimed at addressing the fundamental issue in antipsychotic therapeutics -the balance between mental state benefits and neurological risks.The latter cannot be overestimated and clinical skills in themselves are inadequately sensitive to refine practice. Read more about this study

Who is it for?
Ages 18 to 50 years
Conditions the study is for
Drug-induced Extrapyramidal Side Effects
What is being tested?
Manus Sensor Pen
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
21 participants
Where
1 siteUnited Kingdom
Study dates
21 Feb 2017to 30 Jun 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Patients with an acute psychotic illness requiring admission to hospital
  • Medications are deemed necessary for appropriate clinical management
  • English as a first language
  • Under the age of 50 years (to reduce the likelihood of idiopathic Parkinson's disease)
  • Right-handed
  • Mixed, balanced genders
  • Basic writing competence
  • No previous neurological disease

Who cannot join

  • Lack of capacity as deemed by their Consultant Psychiatrist
  • Under 18 years of age
  • Over 50 years of age
  • Recent use of psychostimulant drugs
  • Previous neurological disease
  • English not a first language
Show all 9Show fewer
  • Left handed
  • Previous neurological condition
  • For Stage 2: antipsychotic medication orally in the previous 3 months or by depot injection in the previous 6 months

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • NHS Lothian

    Edinburgh

Other trials in United Kingdom

About this study

The project is aimed at addressing the fundamental issue in antipsychotic therapeutics -the balance between mental state benefits and neurological risks.The latter cannot be overestimated and clinical skills in themselves are inadequately sensitive to refine practice. With all current and "pipeline" antipsychotics based on central dopamine blockade, there is little prospect that therapeutics can be improved by advances in pharmacology alone.

The project uses, for the first time, technology that is not only simple, real-life and user-friendly but "modern" and socially held in high regards. The proposal depends on patients receiving antipsychotic medication where clinically indicated. At all times, subjects will receive clinically-indicated therapy. The major ethical issue will relate to the issue of informed consent in those suffering from major psychiatric disorder. This is a routine consideration in psychiatric practice and the investigators will seek guidance on this from the Consultant Psychiatrist responsible for potential participants and would not proceed with initial approaches in cases of doubt or absence of capacity.

This is a pilot/feasibility study with no intention to utilise the data for commercialisation of the device or to expand the CE (Conformité Européenne) marking.

Read the detailed description

The proposed methodology is based on use of a computer tablet and modified pen. While these instrumental elements are common-place and widely accepted in modern life, they are not so in the context of formal clinical assessment of motor function in psychiatric patients. They are also novel to clinicians. The first stage will involve recruitment of 20 patients i) under the age of 50 (to reduce the likelihood of idiopathic Parkinson's disease): ii) of mixed, balanced genders: iii) right-handed: iv) basic writing competence: v) English as first language: vi) suffering from an acute psychotic episode. These subjects will have been on stable doses of antipsychotic medication of any sort for at least 2 weeks. Patients will be seated in a comfortable writing position at a table and presented with a graphic tablet and a modified digitizer pen with a wired connection to an operator computer. The assessor will sit slightly behind and to one side out of the subject's view. To familiarise subjects with the technique, they will be asked to a) draw repetitive overlaid circles b) write their name and address, at a speed comfortable to them. They will then be asked to produce the 8 character 'el' text sequence ('elelelel') 10 times and to write a short, standard sentence : "Today is a nice day for the time of year". The examiner will then say to the subject the nursery rhyme, 'Mary had a little lamb...etc" and ask the subject to write it spontaneously from memory. Finally, they will be asked to copy a standard short paragraph from a written page. On conclusion, they will be asked to complete a brief 10cm line, Likert scale of satisfaction, assessing the test situation as 'easy/difficult: 'pleasurable/non-pleasurable':'acceptable/non-acceptable'.

PREDICTION : participants will find the procedures easy, pleasurable and acceptable

2 groups of 10 patients, complying with criteria i)-vi) above, but who have not been exposed to antipsychotic medication for at least 3 months (oral formulations) or 6 months (depot formulations) but in whom antipsychotic medication is now indicated. Groups will comprise consecutive consenting patients prescribed one of two commonly utilised antipsychotics : the high potency, risperidone, and the low potency, quetiapine. Dosages will be determined clinically by the responsible medical officers who will be asked to maintain a standard pattern of escalations : twice weekly and within the first 2 weeks of exposure (but not dose restricted). They will also be asked to avoid additional medications for drug-induced parkinsonism though these may be used on an as required 'rescue' basis. Other medications can be utilised as clinical need determines. Following informed consent, and prior to initiation of treatment, subjects will undertake baseline clinical assessments comprising : a standardised assessment of mental state (Positive and Negative Symptom Scale - PANSS); a standard clinical evaluation of extrapyramidal neurological status (the Extrapyramidal Symptom Rating Scale - ESRS); a standard questionnaire of subjective state (the Subjective Well-Being on Neuroleptics Scale - SWNS - designed to pick up later potential medication effects). They will then complete the instrumental component as above. Assessments will be completed twice weekly during the escalation phase (2 weeks) and weekly thereafter (up to 4 weeks) on the day before increases are implemented.

PREDICTION : instrumental methods will prove highly sensitive to the development of extrapyramidal side-effects and significantly more so than the standard clinical examination: AND : extrapyramidal effects will significantly precede the onset of antipsychotic efficacy

Being tested
Manus Sensor Pen

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Manus Sensor PenDevice

    Manus Sensor Pen as made by Manus Neurodynamica Ltd

Study groups in NCT02366897
Study groupRoleWhat they receive
Tolerability and sensitivityOtherStage 1: tolerability as per study design Stage 2: sensitivity as per study design - either quetiapine or risperidone. The intervention is the use of the Manus sensor pen
Receives: Device: Manus Sensor Pen

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Acceptability to patients with acute psychotic illnesses using the Likert scale of satisfaction, assessing the test situation as 'easy/difficult: 'pleasurable/non-pleasurable':'acceptable/non-acceptable'

    Measured: Stage 1 - One assessment for each patient, allow up to 4 weeks to recruit

  2. Earlier onset (by >1 week) of parkinsonism assessed by micrographic changes compared to standard clinical examination as detected by the Manus sensor pen

    Measured: Stage 2 - each patient shall be in the study for 6 weeks. Allow up to 6 months to recruit.

Secondary outcomes (1)
  1. Sensitivity: prevalence of parkinsonism at different criteria from rating scale parameters as detailed in "description" section below.

    A standardised assessment of mental state (Positive and Negative Symptom Scale - PANSS); a standard clinical evaluation of extrapyramidal neurological status (the Extrapyramidal Symptom Rating Scale - ESRS); a standard questionnaire of subjective state (the Subjective Well-Being on Neuroleptics Scale - SWNS - designed to pick up later potential medication effects)

    Measured: Stage 2 - each patient shall be in the study for 6 weeks. Allow up to 6 months to recruit.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Feb 2015 (estimated)
  2. Study start21 Feb 2017
  3. Primary completion30 Jun 2018
  4. Study completion30 Jun 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
21 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02366897
Sponsor's protocol ID
SensorPen.v.1.0
Status last verified
Jun 2024
First submitted
5 Feb 2015
Last updated
21 Jun 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Manus Sensor Pen in people with Drug-induced Extrapyramidal Side Effects, run by University of Edinburgh at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Acceptability to patients with acute psychotic illnesses using the Likert scale of satisfaction, assessing the test situation as 'easy/difficult: 'pleasurable/non-pleasurable':'acceptable/non-acceptable' (time frame: Stage 1 - One assessment for each patient, allow up to 4 weeks to recruit). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jun 2024; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in